Telehealth Intervention for Infants With Prodromes of ASD
Recruiting
N/AInterventional Study
Autism Spectrum Disorder (ASD)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Ready to participate?
Review the details below, then apply to join this clinical trial.
At a Glance
Age
9 Months – 17 Months
Sex
Any
Study type
Interventional
Purpose
Prevention
Participants needed
132 (estimated)
Sponsor
IRCCS Fondazione Stella Maris · Other
Who this trial is looking for
This trial is looking for infants under 18 months who may show early signs of autism. Participants will receive remote support to help improve development and reduce autism symptoms.
Are You a Good Fit for This Trial?
You may be able to join if
I live in a household where Italian is spoken.
I have a risk-range score at SACS-R.
My infant is under 18 months old.
I have a device with a webcam and internet access.
You may not be able to join if
My child has a known genetic disorder.
My child has brain damage or other serious neurological issues.
My child has severe visual or hearing problems.
My child has a chronic illness that affects their development.
Summarized in plain language from this trial's official eligibility criteria.
The full criteria are further down this page — only the research team can
confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Autism Spectrum Disorder (ASD) is a complex neurodevelopmental disorder characterized by social-communication and interaction deficits and restricted, repetitive patterns of interests and behavior. It is frequently associated with heterogeneous comorbidities including physical, mental, and neurodevelopmental disorders, which can result in a substantial burden on individuals, families, and society.…
Autism Spectrum Disorder (ASD) is a complex neurodevelopmental disorder characterized by social-communication and interaction deficits and restricted, repetitive patterns of interests and behavior. It is frequently associated with heterogeneous comorbidities including physical, mental, and neurodevelopmental disorders, which can result in a substantial burden on individuals, families, and society.
Early prodromal signs of ASD emerge during the first year of life, a time when brain plasticity is at its maximum level, and may consist of diminished social orienting, responsivity and reciprocity combined with the presence of prolonged visual fixation and repetitive use of objects. Developmental immaturities in communication and motor skills are often present too. Pre-emptive Intervention (PI) for infants with prodromal signs of ASD was shown to improve outcomes, in comparison to later starts, by improving developmental skills, reducing ASD symptoms and, in some cases, preventing the full blown symptoms of ASD. Moreover, access to early evidence-based interventions may reduce the elevated levels of stress, anxiety and depressive symptoms experienced by caregivers of children with signs of ASD.
Despite this evidence, professionals tend to have a 'wait to see' approach, rather than targeting areas of impairment with early intervention. Moreover, the vast majority of current clinical models of ASD services require a diagnosis to receive services, while the identification of prodromal signs of the disorders generally is not sufficient to access early intervention. There is an urgent need for a paradigm shift in ASD treatment.
The proposed Project aims to evaluate the efficacy of FIRRST, a parent-mediated PI for infants with early signs of ASD. We will conduct a multisite RCT of telehealth PI by recruiting 132 symptomatic infants between 9-14 months and randomly assigning them to receive either FIRSST (experimental group), or Parent Education (control group). Developmental skills, ASD symptomatology, caregiver well-being and brain changes on High-Density EEG will be assessed with in-presence evaluations at three time points: 1. baseline; 2. after 24 weeks of intervention; 3. follow-up after 24 weeks from the end of intervention.
If funded, The proposed study will be the first well-powered RCT evaluating developmental, symptom and neurophysiological changes in response to a parent-mediated PI conducted in Europe. The ultimate goal for translational research in ASD lies in the optimization of clinical outcomes through the most effective, targeted, and timely treatments. The proposed RCT has the potential to significantly impact current access to services by reducing the age of starting intervention, thereby promoting optimal developmental outcomes, as well as reducing burden and high health costs to families and society.
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Inclusion Criteria:
* risk-range score at SACS-R;
* Italian as one of the languages spoken at home;
* age below 18 months (corrected) at the time of identification;
* available device with webcam and home internet access.
Exclusion criteria:
* presence of a known genetic disorder, brain damage or…
Inclusion Criteria:
* risk-range score at SACS-R;
* Italian as one of the languages spoken at home;
* age below 18 months (corrected) at the time of identification;
* available device with webcam and home internet access.
Exclusion criteria:
* presence of a known genetic disorder, brain damage or other relevant neurological or chronic disorders;
* severe visual, auditory and/or motor impairment.
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.